Ideally, an IQ test measures this general factor of intelligence, abbreviated as g. The best tests, therefore, like the Wechsler Adult Intelligence Scale or the Stanford-Binet test feature ...

Sage plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s after it failed to boost cognitive function in a Phase 2 ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

However, treating IQ test scores as the end-all of learning may ... We were able to find one small 1967 study that used the WAIS to compare the average IQ scores of male scientists at the ...

Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Sage Therapeutics said its Phase 2 trial of dalzanemdor in patients with mild cognitive impairment or mild dementia due to ...

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...

Coding Test score at Day 42," and that "[b]ased on the data, [Sage Therapeutics] does not plan any further development of dalzanemdor (SAGE-718) in PD." On this news, the price of Sage Therapeutics ...